Skip to main content
. Author manuscript; available in PMC: 2008 Dec 1.
Published in final edited form as: Semin Oncol. 2007 Dec;34(6):498–508. doi: 10.1053/j.seminoncol.2007.09.010

Table 3.

Previous studies of SN mapping or clinical recurrence in thin (<1.00 mm) melanoma

Study <0.76 0.76–1.00 ≤ 1.00 Factors
Sentinel node Bedrosian et al35* 1/40 (2.5%) 3/31 (9.7%) 4/71 (5.6%) VGP, no other
Bleicher et al34 2/118 (1.7%) 6/154 (3.9%) 8/272 (2.9%) Age, incomplete biopsy
Jacobs et al44 1/NR 1/NR 2/63 (3.2%)
Kesmodel et al43 1/91 (1.1%) 8/90 (8.9%) 9/181 (5.0%) MR, Br, gender
Lowe et al45 2/NR 1/NR 3/46 (6.5%) Clark ≥ III
Nahabedian et al51 0/NR 2/NR 2/24 (8.3%)
Oliveira Filho et al46 NR NR 6/77 (7.8%) ulceration, MR, VGP
Puleoet al41 NR 20/409 (4.9%) NR None predictive
Wong et al39 0/109 8/114 (7.0%) 8/223 (3.6%) None predictive
Stitzenberg et al36 3/NR 3/NR 6/146 (4.1%) None predictive
Hershko et al37 2/NR 3/NR 5/64 (7.8%) Age
Morton et al30 NR NR 34/465 (7.3%)

Subtotal 3/325 (0.94%) 42/767 (5.5%) 83/1561 (5.3%)

Clinical recurrence Morton et al30 NR NR 238/1979 (12.0%)
Kalady et al50 NR NR 38/1082 (3.5%)
Massi et al52 ** 8/174 (4.6%) 17/113 (15%) 25/287 (8.7%) TIL
Karakousis et al49 21/684 (3.1%) 17/198 (8.6%) 38/882 (4.3%) male,<60,axial
Corsetti et al48 0/NR 5/NR 5/68 (7.4%) Median TTR 52mo
Schmid-Wendtner et al53 37/2301 (1.6%) NR NR male, ALM or LMM
McKinnon et al54 NR NR NR TTR 49.8mo
Woods et al47 5/400 (1.3%) NR NR 2.8% total recur
Naruns et al55 28/649 (4.3%) NR NR male, regression
Subtotal 99/4208 (2.35) 17/198 (8.6) 319/4011 (8.0%)

TOTAL 102/4533(2.3%) 59/965 (6.1%) 402/5572 (7.2%)

VGP, vertical growth phase; MR, mitotic rate; Br, Breslow; NR, not reported; TTR, time to recurrence; TIL, tumor-infiltrating lymphocytes; ALM, acral lentigenous melanoma; LMM, lentigo maligna melanoma

*

These patients also in Kesmodel et al,43 not duplicated in total figures.

**

up to 1.5 mm included, not included in total figures.